Konakion Pediátrico

Phytomenadione, the active ingredient in Konakion Pediátrico, is a vitamin K presented as a pediatric formulation for intramuscular, intravenous, and oral use. It is employed to correct vitamin K deficiency and to prevent hemorrhagic disease in newborns, as well as to reverse anticoagulant effects.

GNH USA supplies Konakion Pediátrico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion Pediátrico (phytomenadione) is used in conditions affecting the vitamin K‑dependent clotting pathway.

- Vitamin K deficiency: restores normal clotting factor activity in patients with insufficient vitamin K. - Hemorrhagic disease of the newborn: prevents bleeding in newborns at risk due to low vitamin K stores. - Anticoagulant reversal: counteracts the effects of warfarin or other vitamin K antagonists to re‑establish hemostasis.

Common Side Effects: - Injection site pain or erythema. - Mild fever or chills. - Nausea or vomiting. - Headache. - Transient elevation of liver enzymes. - Diarrhea.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Acute hemolysis. - Thrombosis or disseminated intravascular coagulation. - Severe hypotension. - Persistent bleeding despite therapy. - Serum sickness-like reaction.

Before administration, assess baseline vitamin K status and coagulation parameters. - Use with caution in patients with liver disease or impaired synthesis of clotting factors. - Avoid in individuals with known hypersensitivity to phytomenadione or any excipients. - Monitor neonates closely for signs of hyperbilirubinemia after dosing. - Do not co‑administer with other vitamin K preparations without medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Major Interactions (Avoid): - Concurrent use with coumarin anticoagulants (e.g., warfarin) without monitoring may cause abrupt reversal of anticoagulation. - Simultaneous administration of other vitamin K products can diminish intended therapeutic effect.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics may alter gut flora and affect endogenous vitamin K levels. - Bile‑acid sequestrants can reduce oral absorption of phytomenadione. - Barbiturates and other enzyme‑inducing drugs may increase vitamin K metabolism. - High‑dose vitamin E may interfere with vitamin K activity. - Oral contraceptives may modestly affect clotting factor synthesis.